An improved benefit-risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received 2 prior therapies

Matthew S. Davids, Peter Hillmen, Marco Montillo, Julio Delgado, Bryone J. Kuss, Constantine S. Tam, Ulrich Jager, Paolo Ghia, Stephan Stilgenbauer, Florence Cymbalista, Stephanie Lustgarten, David T. Weaver, Hagop Youssoufian, Ian W. Flinn

Research output: Contribution to journalMeeting Abstractpeer-review

Abstract

Purpose of the Study: Despite effective frontline therapies, many patients with CLL or SLL eventually relapse and require additional therapies to control their disease. Duvelisib, a first-in-class oral dual PI3K-, inhibitor, was approved by the FDA for the treatment of relapsed or refractory CLL or SLL after 2 prior therapies. Here we present the efficacy and safety of duvelisib in patients who had received 2 prior therapies in the phase 3 DUO trial (NCT02004522).
Original languageEnglish
Article numberP-012
Pages (from-to)S9-S10
Number of pages2
JournalAMERICAN JOURNAL OF HEMATOLOGY
Volume94
Issue numberS2
DOIs
Publication statusPublished - 1 Nov 2019
Externally publishedYes

Keywords

  • chronic lymphocytic leukemia
  • small lymphocytic lymphoma
  • CLL
  • SLL
  • therapies
  • patients
  • Duvelisib

Fingerprint

Dive into the research topics of 'An improved benefit-risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received 2 prior therapies'. Together they form a unique fingerprint.

Cite this